Search

Displaying results 2831 - 2840 of 10000 in total
  1. Drug

    Nomegestrol acetate

    go.drugbank.com/drugs/DB13981
    Approved

    Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders.

    Categories: Hormonal Contraceptives for Systemic UseSynonyms: 17-alpha-Acetoxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione
  2. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018. … [L2502] Sinapultide is a 21-residue peptide made up of lysine (K) and leucine (L) residues with the sequence KLLLLKLLLLKLLLLKLLLLK (KL4), in aqueous dispersion with the phospholipids DPPC (dipalmitoylphosphatidylcholine

  3. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019. … [L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India.

  4. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. … Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.

  5. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  6. Drug

    Pargyline

    go.drugbank.com/drugs/DB01626
    Approved

    Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  7. Indication

    Memory Disturbances

    go.drugbank.com/conditions/DBCOND0054216
    Drugs: Aniracetam
    Synonyms: Poor memory
  8. Drug

    Beet

    go.drugbank.com/drugs/DB10640
    Approved

    Beet allergenic extract is used in allergenic testing.

    Mixtures: Anbiser B-HA Hyaluronic Acid Nourishing Conditioner
  9. Drug

    Oxaliplatin

    go.drugbank.com/drugs/DB00526
    ApprovedInvestigational

    [A797] Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal … Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin.

    Categories: OCT2 Substrates with a Narrow Therapeutic IndexSynonyms: L-OHP, (SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM
  10. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements … Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.